Can AI draft my comprehensive eye exam SOAP notes?

Yes — ambient scribes (DeepScribe, Abridge, Suki, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai) under a HIPAA BAA can draft the SOAP note including chief complaint, ocular + systemic history, visual acuities, refraction, slit-lamp, IOP, DFE + OCT / fundus photo findings, assessment, and plan with CPT 92002 / 92004 / 92012 / 92014 / 92015 / 92250 / 92133 / 92134 / 92083. The OD signs and owns the record under state optometry-board scope-of-practice, AOA ethics, and ONC HTI-2 information-blocking rules. AI-draft disclosure is required or recommended by state in CA (AB 3030), UT, and expanding — check current law before deploying.

Is AI retinal screening (IDx-DR, EyeArt, AEYE-DS) allowed in an optometry office?

Yes — FDA-cleared autonomous DR screening (IDx-DR de novo 2018, EyeArt 510(k) 2020, AEYE-DS 510(k) 2022) is explicitly indicated for primary care and optometry deployment. CMS CPT 92229 covers automated point-of-care diabetic-retinopathy exam in an optometry office. Scope-of-practice for diagnosis + referral follows state optometry-board rules — some states require MD referral for positive findings, others do not. Document informed consent, image quality flag, and device-limitation disclosure in the encounter note.

Can AI generate contact lens prescriptions or myopia control treatment plans?

No — the Rx is the doctor's clinical decision and legal act. AI can draft the CL fitting work-up (base curve, diameter, material, wearing schedule), OrthoK design brief (Paragon CRT, Euclid, GOV), soft multifocal myopia-control plan (MiSight, NaturalVue Multifocal), or atropine 0.025% / 0.05% taper — but the OD reviews, overrides, signs, and assumes responsibility. FTC Contact Lens Rule 16 CFR 315 and the Fairness to Contact Lens Consumers Act require the patient receive a copy of the CL Rx and the OD verify within 8 business hours of any third-party seller request.

How do we stay FTC-compliant when our optical dispensary and online ads discuss vision improvement?

FTC Eyeglass Rule 16 CFR 456 requires immediate free copy of the eyeglass Rx after the refraction. FTC Contact Lens Rule 16 CFR 315 requires the same for CLs + verification window. FTC Act §5 UDAP + Endorsement Guides 2023 prohibit deceptive claims; AI-drafted testimonials must reflect typical results with material-connection disclosure when applicable. State truth-in-advertising (CA B&P §17500, FL §817.06, NY GBL §349, TX DTPA §17.46) apply to outcome claims for myopia control, dry-eye therapy, vision therapy, and scleral lens rehab.

What's the single highest-ROI AI deployment for a 1-5 OD optometry practice?

Ambient scribing of the comprehensive eye exam + AI retinal screening are tied for #1. Ambient scribing recaptures 45-90 seconds per patient across 20-30 exams/day (≈1 added encounter/day). AI retinal screening (EyeArt / IDx-DR / AEYE-DS) unlocks CPT 92229 billing + catches referable DR / AMD / glaucomatous cupping that would have been referred out — both add practice revenue + quality. Second tier: a NexHealth / Weave recall that cleans lapsed-annual-exam rosters and an OCT AI overread (Notal Home OCT, RetinAI, Heidelberg Eye Explorer AI) for AMD + glaucoma surveillance.

Published May 13, 2026 · 16 min read · How-To Guide

How to Use AI for an Optometry Practice in 2026: Owner's Playbook

TL;DR for optometrist-owners

The 2026 OD-owner AI stack is RevolutionEHR / Crystal PM / Compulink Advantage Eye Care / OfficeMate + Eyefinity / My Vision Express / CrystalPM + DeepScribe / Abridge / Suki / Nuance DAX Copilot / Heidi / Freed / Sunoh.ai for ambient-scribed comprehensive eye exams + Optos Silverstone / Eidon / iCare EIDON AF / Zeiss Cirrus 6000 / Heidelberg Spectralis / Topcon Maestro2 / Triton + EyeArt / IDx-DR / AEYE-DS / RetinAI / Eyenuk / Notal Home OCT for retinal + OCT AI overread + Visionix VX650 / Optovue Solix / Topcon Triton OCTA + Visionix VX130 / Topcon KR-1W / NIDEK ARK-1s for auto-refraction + biometry + Oculus Keratograph 5M / LipiView II / iLux / TearLab / InflammaDry for dry eye + Weave AI / NexHealth / Doctible / Solutionreach / RevenueWell for recall + Yelp / Google Business Profile / BirdEye / Podium for reviews. Keep AI on the doctor's edit queue — never autonomous Rx generation, never autonomous referral decisions, never autonomous DR diagnosis beyond FDA-cleared-autonomous scope (IDx-DR / EyeArt / AEYE-DS). Ground every prompt in a compliance floor (HIPAA BAA, FDA 510(k) for AI-SaMD, AOA ethics, state optometry-board scope, ONC HTI-2, FTC 16 CFR 456 + 315, Fairness to Contact Lens Consumers Act, AKS / Stark, state AI-scribe consent). 10 copy-paste prompts below.

The compliance floor (non-negotiable for every prompt)

Every AI deployment in your OD office must be mapped to:

HIPAA 45 CFR 160 / 164 — signed BAA with every AI vendor that touches PHI (ambient scribe, retinal AI, OCT AI, communication, recall, chat).
HHS OCR Reproductive Health Privacy Final Rule 2024 — minimum-necessary defaults for pregnancy-related vision changes (gestational DR, hypertensive retinopathy).
ONC HTI-2 2024 final rule + USCDI v4 + 8 information-blocking exceptions (Prevent Harm, Privacy, Security, Infeasibility, Content and Manner, Fees, Licensing, TEFCA Manner). AI-draft clinical notes are patient-accessible under 21st Century Cures info-blocking rule.
FDA 510(k) AI-SaMD framework + 2024 PCCP guidance — every autonomous diagnostic AI (IDx-DR, EyeArt, AEYE-DS, Eyenuk, RetinAI, Notal Vision Home OCT, Heidelberg AI) must have FDA clearance for its claimed use + documented Predetermined Change Control Plan.
State AI-scribe + AI-use consent — CA AB 3030 (effective Jan 2025 — patient-facing GenAI disclosure), UT HB 452 (AI Mental Health Policy Act), TX SB 815 (eff Sep 2025), IL HB 1806 (eff Jan 2026), NY S1331A (pending). Disclose AI-drafted exam notes + AI-drafted patient communication as required.
AOA Standards of Professional Conduct + Code of Ethics — OD retains full responsibility for diagnosis, Rx, referral, and record. AI is a draft tool; the OD signs.
State optometry-board scope of practice — pharmaceutical privileges (CA / FL / NY / TX / NJ allow oral meds for OD; states vary on laser YAG capsulotomy / SLT / LPI — KY / LA / OK / AR / MS / CO / VA / WY / WA / UT have statutory laser expansions as of 2024-2025). Never draft beyond your state scope.
FTC Eyeglass Rule 16 CFR 456 — release copy of eyeglass Rx immediately after refraction, without conditions, without charge, without requiring purchase of glasses.
FTC Contact Lens Rule 16 CFR 315 + Fairness to Contact Lens Consumers Act — release CL Rx after fitting; 8-business-hour passive verification window for third-party sellers; no package requirements; "automated telephone system" verification rules updated 2020.
AKS / Stark + state self-referral — optical + optometric-medical co-ownership structures must respect AKS safe harbors + Stark exceptions; VSP / EyeMed / Davis Vision / Spectera panel contracts layer on separate anti-kickback rules.
FTC Act §5 UDAP + Endorsement Guides 2023 + 2024-2025 updates + state truth-in-advertising (CA B&P §17500, FL §817.06, NY GBL §349, TX DTPA §17.46). AI-drafted testimonials must reflect typical results + material-connection disclosure.
TCPA + state mini-TCPA (CA, FL, MA, WA, PA, IL, MT, NH, CT, MD) + quiet hours 8am-9pm local — AI-drafted SMS recall must respect consent tier, frequency cap, and opt-out.
PCI-DSS 4.0 (full enforcement March 2025) — any payment data flowing through AI chat / AI phone must sit inside a PCI-attested path.

The 2026 OD-owner AI stack

Practice management + EHR: RevolutionEHR + Revo AI / Crystal PM / Compulink Advantage Eye Care / OfficeMate + Eyefinity / My Vision Express / Maximeyes / Uprise / OD Link / Acuity Logic.
Ambient scribe: DeepScribe / Abridge / Suki Assistant / Nuance DAX Copilot / Heidi / Freed / Sunoh.ai — all must be under a HIPAA BAA.
Retinal + OCT AI overread: IDx-DR / EyeArt / AEYE-DS / RetinaLyze / RetinAI Discovery / Eyenuk EyeArt / Optos Silverstone (ultrawidefield + AI) / Eidon UWF AI / iCare EIDON AF / Notal Vision Home OCT (AMD self-monitoring — FDA De Novo 2023).
OCT platforms: Heidelberg Spectralis + Heidelberg Eye Explorer AI / Zeiss Cirrus 6000 + PLEX Elite / Topcon Maestro2 + Triton + DRI OCT Triton / Optovue Solix + AngioVue / Nidek RS-330.
Auto-refraction + biometry + topography: Visionix VX650 / VX130 / Topcon KR-1W + CV-5000 + TRK-3P / NIDEK ARK-1s + RT-6100 / Zeiss i.Terminal 2 + VISUFIT + IOLMaster 700 / Oculus Pentacam + Corvis ST + Keratograph 5M / Heidelberg Anterion.
Dry-eye diagnostics + therapy: Oculus Keratograph 5M / LipiView II / LipiFlow / iLux / TearLab Osmolarity / InflammaDry / BlephEx / MiBo Thermoflo / OptiLight IPL / TearCare / EyeXpress.
Myopia control + contact lens: MiSight 1-day / NaturalVue Multifocal / Essilor Stellest (intl) / Hoya MiYOSMART (intl) / Paragon CRT / Euclid Max / Menicon Z Night / GOV / atropine 0.025% / 0.05% compounding pharmacies.
Recall + reviews + communication: Weave AI / NexHealth / Doctible / Solutionreach / RevenueWell / Demandforce / Klara / BirdEye / Podium / Swell / NiceJob.
Insurance + claims + vision plan: VSP On Demand / EyeMed eClaim / Davis Vision / Spectera / Avēsis / Superior Vision / Office Ally / Availity / Waystar / CoverMyMeds for medical-model prior auth.
General drafting + research: ChatGPT Plus / Enterprise / Claude Pro / Team / Gemini Advanced / Happycapy Pro — no PHI without a BAA in place for the specific tenant.

10 copy-paste prompts (OD-owner edition)

1. New-patient intake + chief-complaint triage

Synthesize the new-patient questionnaire + prior records into an exam-ready intake.

You are an ophthalmic technician drafting an intake summary for <patient name>, DOB <##>, seen by Dr. <name> on <date> for <chief complaint>. Source documents: <pasted intake form + prior Rx + prior records>. Produce: - Chief complaint in patient's words. - Ocular history: glasses / CL wear schedule, LASIK / PRK / ICL, cataract surgery + IOL type, glaucoma + drops, macular disease, retinal detachment, uveitis, strabismus / amblyopia, dry eye + therapies tried. - Systemic history: diabetes (last A1c + duration), hypertension, autoimmune, thyroid, migraine, sleep apnea, pregnancy, medications (flag hydroxychloroquine / tamoxifen / amiodarone / topiramate / steroids / ethambutol / isotretinoin / tamsulosin for IFIS), allergies. - Family ocular history: glaucoma, AMD, diabetic retinopathy, RD, keratoconus, strabismus, color deficiency. - Red flags for same-day escalation: sudden vision loss, flashes / floaters, curtain, diplopia, giant-cell-arteritis symptoms, acute angle closure symptoms, chemical splash, penetrating injury. - Suggested exam plan: refraction, DFE vs undilated, OCT-macula, OCT-ONH + RNFL, HVF / Matrix, fundus photo / UWF, pachymetry, topography, CL work-up, dry-eye panel, binocular vision. - Pre-fill the tech chart fields: VA, pinhole, IOP plan, autorefractor, lensometry, cover test, pupils, EOMs, confrontation fields, color vision. Flag any item the OD must personally verify. Do not generate a refractive Rx. Do not finalize a diagnosis.

2. Ambient-scribed comprehensive eye exam SOAP

Convert the ambient recording into the SOAP note the OD signs.

You are a HIPAA-BAA-covered ambient scribe drafting the SOAP note for Dr. <name>, patient <MRN>, DOS <date>, visit type <comprehensive eye exam / follow-up / CL fitting / DFE / medical office visit>. Produce: - SUBJECTIVE: chief complaint verbatim, HPI (OLDCARTS for any symptom), ROS pertinent to ocular + systemic, ocular + systemic + family history update, medications + allergies update, social (occupation, hobbies, driving, screen time, UV exposure), last eye exam + Rx history, CL wear + hygiene. - OBJECTIVE: DVA + NVA cc / sc + pinhole, autorefractor, manifest refraction, cycloplegic refraction (if performed), BCVA, lensometry, EOMs, cover test (distance + near), NPC, stereo, color (Ishihara / HRR), confrontation fields, pupils (PERRLA + APD), slit-lamp (lids / lashes / conj / cornea / AC / iris / lens / ant vit) with grading, IOP (GAT / iCare / NCT with time), pachymetry, gonioscopy (if performed), DFE (optic nerve C/D + rim + RNFL + vessels + macula + periphery all four quadrants), OCT-macula + OCT-ONH summary, HVF summary, fundus photo + UWF callouts. - ASSESSMENT: ICD-10 primary + secondary (e.g., H52.223 myopia, H25.11 nuclear cataract, H35.3221 intermediate dry AMD OD, H40.11X1 mild POAG OD, H04.123 dry eye bilateral, H52.211 regular astigmatism OD). - PLAN: refractive Rx + ADD if any, CL plan, medication changes, glaucoma target pressure + follow-up interval, DFE interval, referral (retina / glaucoma / cornea / oculoplastics / neuro-ophth / PCP / endocrine), patient education topics, RTC interval. CPT: choose from 92002 / 92004 / 92012 / 92014 (routine) or 99202-99205 / 99212-99215 (medical E/M) + special-testing add-ons 92015, 92020, 92083, 92133, 92134, 92250, 92227, 92228, 92229. Document MDM supporting E/M level. Note whether MIPS PI / Quality / Promoting Interoperability measures were captured. Flag any finding Dr. <name> must personally confirm before sign-off. Mark AI-drafted per state (CA AB 3030 / applicable state law). The doctor signs.

3. AI retinal screening + DR / AMD / glaucoma overread

Draft the point-of-care retinal screening note tied to CPT 92229 + OCT overread triage.

You are drafting the point-of-care retinal screening + OCT overread note for patient <MRN>, diabetic <type 1 / 2>, last A1c <##>, on <platform IDx-DR / EyeArt / AEYE-DS>, with OCT-macula on <Cirrus 6000 / Spectralis / Maestro2 / Triton>. Produce: - Image-quality attestation + any gradable vs ungradable flag. - IDx-DR / EyeArt / AEYE-DS output (negative vs mtmDR-positive + referral recommendation). - Manual overread by OD: DR severity (no DR / mild / moderate / severe NPDR / PDR), CSME presence, AMD (early / intermediate / late dry / wet), glaucomatous ONH findings (RNFL defect, NRR thinning, disc hemorrhage, C/D asymmetry ≥0.2), epiretinal membrane, vitreomacular traction, peripheral findings. - CPT: 92229 (autonomous point-of-care DR screening) OR 92227 (remote imaging with analysis by clinician) OR 92228 (remote imaging with interpretation + report) — pick based on workflow. Add 92133 / 92134 / 92250 as indicated. - Referral routing: retina (urgent <same day / 24-48 hr / 1-2 weeks>, routine <4-6 weeks>), glaucoma specialist, neuro-ophthalmology. Send AAO-compliant referral letter. - Patient-facing plain-English explanation: what was found, what it means, next step, urgency, cost expectation. Respect FDA-cleared-autonomous scope: IDx-DR / EyeArt / AEYE-DS are indicated for DR screening in primary-care / optometry settings, not for AMD or glaucoma diagnosis. OD is responsible for beyond-DR findings. Document AI-assistance per state disclosure law.

4. Contact lens + myopia control treatment plan draft

Draft the CL fitting + myopia-control plan; OD reviews and writes the Rx.

You are drafting a CL + myopia-control treatment plan for patient <MRN>, age <##>, Rx OD <sph/cyl/axis>, OS <sph/cyl/axis>, K-readings OD <K1/K2/axis>, OS <K1/K2/axis>, HVID <##>, axial length OD <## mm>, OS <## mm>, progression <## D / year>, parental myopia <yes / no>, lifestyle <outdoor hours / screen hours / sports>. Produce: - Fitting candidates ranked with rationale: - Soft multifocal myopia control: CooperVision MiSight 1-day (FDA-approved age 8-12 start), NaturalVue Multifocal (off-label myopia-control evidence). - Ortho-K: Paragon CRT / CRT Dual Axis, Euclid Max, Menicon Z Night, Global OK Vision (GOV), Wave — BC + target + lens-diameter starting point. - Soft CL standard: silicone hydrogel (senofilcon, comfilcon, samfilcon, lotrafilcon) daily disposable preferred, monthly acceptable. - RGP / scleral for keratoconus / post-refractive / high astigmatism / dry-eye rehab. - Pharmacologic adjunct: low-dose atropine 0.025% / 0.05% nightly (LAMP, CHAMP, WA-ATOM data) — compounding pharmacy + parental informed consent template. - Wearing schedule + replacement interval. - Follow-up calendar: 1-week, 1-month, 6-month, annual + axial-length tracking with Zeiss IOLMaster 700 / Heidelberg Anterion / Topcon MYAH / Haag-Streit Lenstar. - Parent-facing education: expected progression slowing ~50-60% (varies by modality), not cure, continues until early 20s, safety of CL wear in children (CooperVision + Brien Holden Vision Institute safety data). Flag items requiring OD verification: final Rx, base curve, material, replacement schedule, atropine concentration + compounding pharmacy, informed-consent signing. OD signs the CL Rx. Respect FTC Contact Lens Rule 16 CFR 315 — release Rx to patient + verify 8-business-hour window for third-party sellers.

5. Dry-eye TFOS DEWS II + treatment pathway

Draft the dry-eye work-up, staging, and stepped treatment plan per TFOS DEWS II.

You are drafting a TFOS DEWS II-compliant dry-eye plan for patient <MRN>, symptoms <OSDI / SPEED / DEQ-5 score>, Keratograph 5M NIKBUT <##>, TMH <##>, meibography grade <##>, TearLab osmolarity OD <##> / OS <##>, InflammaDry MMP-9 <pos / neg>, Schirmer <## mm>, lissamine green / fluorescein staining <Oxford grade>, lid margin findings, Demodex <yes / no>. Produce: - Classification: aqueous-deficient vs evaporative vs mixed, with MGD grade per Arita / Korb. - Staging per TFOS DEWS II: Stage 1-4 with trigger findings. - Stepped management: - Step 1: education, environmental modification, lid hygiene (Ocusoft / Cliradex / Avenova), preservative-free artificial tears, omega-3 (Nordic Naturals ProEPA / PRN EyeOmega), warm compress (Bruder / TheraPearl), topical Demodex if T. brevis (Xdemvy 0.25% lotilaner FDA-approved July 2023). - Step 2: prescription anti-inflammatory (cyclosporine 0.05% Restasis / 0.09% Cequa / 0.1% Vevye, lifitegrast Xiidra, short-course loteprednol Eysuvis / Inveltys / Lotemax), autologous serum tears, in-office MGD therapy (LipiFlow, iLux, TearCare, MiBo, OptiLight IPL, low-level light therapy Eyelight / Celluma). - Step 3: oral doxycycline / minocycline / azithromycin for MGD + ocular rosacea, punctal occlusion (collagen → silicone plugs → thermal cautery), therapeutic CL, amniotic membrane (Prokera / Bio-Tissue AmnioGraft / ProKera Slim / ProKera Plus). - Step 4: surgical + refractory management. - Billing: CPT 92072 (scleral CL fit) / 92071 (therapeutic CL) / 65778-65780 (amniotic membrane) / 68761 (punctal plug) / 0563T-0565T (thermal pulsation — carrier-specific). - Patient-facing plain-English plan + expectations (dry eye is chronic + managed, not cured). Respect FDA-approved indications for every drug + device cited. Note off-label use when prescribing outside label. OD signs all Rx + plans.

6. Glaucoma suspect / POAG follow-up workflow

Draft the glaucoma suspect / POAG follow-up note + target-IOP management plan.

You are drafting a glaucoma suspect / POAG follow-up note for patient <MRN>, diagnosis <H40.01X open-angle / H40.11X POAG / H40.02X suspect>, stage <mild / moderate / severe>, baseline IOP + current IOP, CCT, gonio, HVF pattern (SAP 24-2 / 10-2 SITA Standard / Faster), MD / PSD / VFI trend, OCT-RNFL sectoral + GCL, ONH photo / disc stereo. Produce: - Trend summary (GPA / Guided Progression Analysis / OCT event + trend analysis / HVF SITA Faster compared to baseline). - Target IOP per AAO Preferred Practice Pattern (20-30% reduction from baseline, lower for severe, lower for NTG with documented progression). - Medication review: current drops, adherence, technique, side effects, cost. Stepped escalation: prostaglandin analog (latanoprost / travoprost / bimatoprost / tafluprost / latanoprostene bunod Vyzulta), beta-blocker, alpha-2 agonist (brimonidine), CAI (dorzolamide / brinzolamide), Rho-kinase inhibitor (netarsudil Rhopressa / Rocklatan). Preservative-free if ocular-surface disease. Generic vs brand cost note. - SLT / iStent / Hydrus / OMNI / Durysta / sustained-release implant referral criteria. For states with laser privileges (KY / LA / OK / AR / MS / CO / VA / WY / WA / UT — verify current scope), flag SLT as same-practice option; else refer to glaucoma specialist. - Follow-up interval: HVF + OCT-RNFL cadence per stage (suspect q12mo baseline, mild q6-12mo, moderate q4-6mo, severe q2-4mo). - Patient-facing explanation: compliance coaching, night-time progression risk, driving + tunnel-vision counseling. CPT: 92083 (extended VF), 92133 (OCT-ONH), 92134 (OCT-macula), 92136 (biometry), 92250 (fundus photo), 92285 (anterior seg imaging). OD signs the plan.

7. Optical dispensing + FTC Rx-release + warranty SOP

Draft the FTC-compliant optical-dispensary SOP + warranty letter.

You are drafting the optical dispensary SOP + patient-facing warranty letter for <practice name> in <state>. SOP must address: - FTC Eyeglass Rule 16 CFR 456: release eyeglass Rx to patient IMMEDIATELY after refraction, in writing, free of charge, no conditions, no requirement to purchase. Rx expiration minimum 1 year (state may extend). - FTC Contact Lens Rule 16 CFR 315 + Fairness to Contact Lens Consumers Act: release CL Rx after successful fitting, free of charge, minimum 1-year validity or state-extended, passive verification with third-party sellers within 8 business hours, no requirement to purchase CLs from practice. - Dispensing workflow: frame measurement + seg height + PD (monocular + binocular) + PAL fitting height + vertex distance + pantoscopic tilt + face-form angle + back-vertex power + Zeiss VISUFIT / Essilor M'Eye Touch / iVision Center 3D fitting tech. - Lens choice matrix: material (CR-39 / poly / Trivex / 1.60 / 1.67 / 1.74), design (SV / round-top bifocal / PAL by corridor length + category), AR coating, Transitions / Transitions XTRActive / Transitions Gen S, polarized, blue-light filter (evidence-based disclosure — no 'prevents eye disease' claim), Zeiss / Essilor / Hoya / Shamir / Vision Ease / Jobson lens brand tiering. - Warranty: scratch, breakage, Rx-adapt (non-adapt to PAL or new Rx), 1-year or 2-year per tier, remake + credit terms, frame-only vs lens-only, craftsmanship vs abuse. Draft a patient-facing 1-page warranty letter: what is covered, what is not covered, how to file, how long, phone + email for claims. FTC-safe language: no false scarcity, no fake reviews, no deceptive 'free' claims, typical-result disclosures on adaptation. Respect state UDAP (CA B&P §17500 / FL §817.06 / NY GBL §349 / TX DTPA §17.46). Owner signs the SOP. Front-desk trained + tested on FTC Rx-release rule quarterly.

8. Recall + reactivation campaign (annual exam + CL supply + DFE)

Draft a TCPA + HIPAA-safe recall campaign across 4 segments.

You are drafting a multi-channel recall campaign for <practice name> in <state> with <##> lapsed patients across 4 segments. Stack is Weave AI / NexHealth / Doctible / Solutionreach / RevenueWell / Demandforce. Segments: - Annual CEE lapsed 14-24 months. - CL supply lapsed 9-14 months (CL Rx expired or expiring). - Diabetic DFE lapsed 10-14 months (HEDIS Diabetic Eye Exam measure). - Glaucoma / AMD / post-cataract / post-refractive under-active (missed q6 follow-up). For each segment produce a 3-touch sequence (SMS → email → voicemail drop): - SMS touch 1: brief, branded, ≤160 chars, clickable booking link, STOP keyword, practice phone. - Email touch 2: 1 value-add educational item (seasonal dry eye, UV + AMD, diabetes + eye, myopia control for kids), booking CTA, opt-out footer. - Voicemail drop touch 3 (ringless-voicemail only where legal, never auto-dialer to cell without prior express written consent): short, warm, names the OD, booking phone. Respect: - HIPAA minimum-necessary: no diagnoses in SMS / voicemail, no medication names. - TCPA + state mini-TCPA (CA / FL / MA / WA / PA / IL / MT / NH / CT / MD): prior express consent for marketing SMS to mobile, STOP + HELP keywords, quiet hours 8am-9pm local, frequency cap (max 2 marketing SMS / week / patient), do-not-call list honor. - State AI-disclosure: note automated / AI-drafted where applicable (CA / UT / TX / IL / NY rules). - Vision-plan co-marketing terms with VSP / EyeMed / Davis / Spectera (plan approval required for plan-branded language). Provide a KPI plan: target reactivation rate by segment (benchmark 15-25% for CL, 8-15% for annual, 20-30% for diabetic DFE where insurance covers).

9. HIPAA + FTC-safe public review reply

Draft the 1-5 star review replies without leaking PHI or violating FTC Endorsement Guides.

You are drafting replies to public reviews (Google Business Profile / Yelp / Healthgrades / Vitals / Zocdoc) for <practice name>. Inputs: <pasted review text + star rating + reviewer name if provided>. Rules: - NEVER confirm or deny the reviewer is a patient. HIPAA 45 CFR 164.502(a)(1)(iv) — unsolicited public engagement does not waive PHI. Responding with 'we treated your dry eye' is an OCR enforcement action. - NEVER reference any clinical detail mentioned in the review, even if the reviewer disclosed it first. - FTC Endorsement Guides 2023: if practice solicited the review, that must be disclosed; if any incentive was offered (gift card, discount, raffle entry), material connection must be disclosed; 'good reviews only' solicitation is a deceptive review-gating violation under FTC Fake Reviews Rule 2024. Draft: - 5-star: warm thank-you, invite to call / email privately for any questions, no clinical reference. - 4-star: warm thank-you, invite to private contact to discuss anything that kept it from 5, no rebuttal, no clinical reference. - 3-star: apology for any gap, explicit invitation to call OD / practice manager at <phone>, commitment to listen, no defensive language, no clinical reference. - 1-2 star: short, non-defensive, apology for the experience described, invitation to private contact with phone + email + office-manager name, offer to investigate, NEVER admit fault, NEVER reference clinical care, NEVER blame vision plan or staff publicly. Each reply ≤400 chars, reads as human + practice-branded. OD / practice manager edits + posts. Log the reply for your review-management SOP.

10. OD-owner monthly scorecard + state-compliant ad

Draft the 1-page monthly KPI scorecard + a state-compliant ad headline set.

You are drafting the monthly OD-owner scorecard + a state-compliant ad set for <practice name> in <state>. Scorecard (month-over-month + YoY): - Exams: total CEE, new patient count, returning patient count, no-show rate, same-day cancel rate, chair utilization %. - Revenue: CEE revenue, medical E/M revenue, optical capture rate, optical revenue / exam (second-pair rate, PAL rate, AR + Transitions capture, sunwear attach), CL revenue / exam, medical-model revenue (92xxx special testing + 99xxx E/M + SLT / AMT / IPL / thermal-pulsation if in scope), VSP / EyeMed / Davis / Spectera effective-rate reconciliation. - Clinical quality: CPT 92229 autonomous DR screening count, HEDIS Diabetic Eye Exam attestation rate, AMD OCT-macula surveillance, glaucoma HVF + OCT-RNFL cadence compliance, MIPS Quality + Promoting Interoperability + Improvement Activities + Cost score. - CL: new fits, re-fits, dropouts, 12-month retention, myopia-control starts + axial-length tracking completeness. - Recall: recall-engine send volume, book-rate by segment, reactivation revenue. - Review ops: new Google / Yelp reviews by star, average rating, response rate, response-time median. - Front-desk: missed-call rate (CallRail), first-ring answer rate, average hold time. - OD-labor productivity: exams / hour, techs / OD, tech utilization, no-show-adjusted schedule fill. Ad headline set (for Google + Meta + local newspaper): - Respect state optometry-board ad rules + FTC Endorsement Guides (no fake reviews, no 'best in town' without objective basis, no 'FDA-approved' for off-label myopia control where not labeled, no guaranteed-outcome language). - No cash-discount-for-insurance-covered-service language. - No package that couples refraction + optical purchase in FTC Eyeglass Rule violation. - Include: location, services offered in scope, accepted vision + medical plans, cancellation / no-show policy, accessibility, Spanish-language availability if applicable. OD signs + ads manager approves before any paid placement.

Common mistakes to avoid

Using a consumer LLM for PHI. ChatGPT Free / Claude.ai Free / Gemini consumer are not BAA-covered. Use the enterprise tenant with a BAA, or purpose-built scribes (DeepScribe, Abridge, Suki, DAX).
Letting AI finalize refractive or CL Rx. The OD signs. AI drafts candidates; the doctor overrides.
Breaking FTC Eyeglass / Contact Lens Rules. Rx release must be free + immediate. Third-party CL verification must complete within 8 business hours.
Autonomous DR diagnosis beyond FDA scope. IDx-DR / EyeArt / AEYE-DS are cleared for DR screening only. AMD, glaucoma, tumors must be OD-overread.
PHI leak in public review reply. Never confirm or reference treatment. Private contact for any clinical thread.
Missing state AI-disclosure. CA AB 3030, UT, TX, IL, NY rules are live / rolling. Disclose AI-drafted patient communication where required.
Cross-state optometric scope drift. Oral meds, laser (SLT / YAG / LPI), AMT, in-office procedures vary by state. Never draft beyond your board's scope.

60-day rollout

Week 1-2: BAA audit every vendor touching PHI (EHR, scribe, retinal / OCT AI, recall, chat). Pick one ambient scribe + pilot with one OD. Document state AI-disclosure compliance.
Week 3-4: Launch AI retinal screening with CPT 92229 workflow. Train techs on image-quality attestation. Start HEDIS diabetic-eye measure attestation cadence.
Week 5-6: Recall-engine segmentation live across 4 segments with TCPA + state mini-TCPA compliance. Review-reply SOP trained with HIPAA guardrails. Optical-dispensary FTC Rx-release training.
Week 7-8: Myopia-control program launch (MiSight + atropine + axial-length tracking). Dry-eye TFOS DEWS II pathway live. Monthly OD-owner scorecard dashboard running.

Want the 1-page compliance + scorecard PDF?

Happycapy Pro keeps your optometry-practice AI stack mapped to HIPAA, FDA AI-SaMD, AOA ethics, state optometry-board scope, FTC 16 CFR 456 + 315, and state AI-disclosure rules — all without leaving the chat.

Back to blog